Hutchison China Meditech LTD (HCM)


HCM Share PerformanceMore

52 week high2,896.50 09/12/15
52 week low1,612.50 28/04/16
52 week change -17.50 (-0.96%)
4 week volume208,181 03/09/16

Latest NewsMore

Broker Forecast - Panmure Gordon issues a broker note on Hutchison China Meditech Ltd

Panmure Gordon today reaffirms its buy investment rating on Hutchison China Meditech Ltd (LON:HCM) and set its pri...

Director Deals - Hutchison China Meditech Ltd (HCM)

Christopher Nash, Non Executive Director, bought 3,162 shares in the company on the 9th August 2016 at a price of 1899.50...

Director's Share Dealing

RNS Number: 6317G Hutchison China Meditech Limited 09 August 2016 Director's Share Dealing London: Tuesday, August 9 , 2016: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notification that the spouse of Mr Christopher Nash, Independent Non-executive Director, has purchased 3,120 and 42 ordinary shares of US$1.00 each in ...

Change of Non-executive Directors

RNS Number: 9555F Hutchison China Meditech Limited 02 August 2016 Change of Non-executive Directors London: Tuesday, August 2 , 2016: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces with effect from August 1, 2016 , Dr Dan Eldar has been appointed as a Non-Executive Director of Chi-Med in place of Mr Salbaing who...

Chi-Med revenues rise

Hutchison China MediTech reports group revenue up 27% to $104.5 million in the six months to the end of June (H1 2015: $...

Chi-Med 2016 Interim Results

RNS Number: 9446F Hutchison China Meditech Limited 02 August 2016 Hutchison China MediTech Limited ("Chi-Med") Reports Interim Results for the Six Months Ended June 30, 2016, Provides 2016 Financial Guidance and Updates Shareholders on Key Clinical Programs Group r evenue up 27% to $104.5 million (H1 2015: $82.5m) and n et income attributable to Ch...

Chi-Med and AZ to accelerate savolitinib

Chi-Med and AstraZeneca have amended the 2011 global licensing, co-development, and commercialisation agreement rega...

Chi-Med and AstraZeneca to Accelerate Savolitinib

RNS Number: 7926F Hutchison China Meditech Limited 01 August 2016 AstraZeneca PLC ("AstraZeneca") (LON/STO/NYSE: AZN) Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) Chi-Med and AstraZeneca A mend C o-development A greement to A ccelerate S avolitinib Global Development Program First g lobal pivotal Phase III in c-Met -dr...

Equity Research (HCM)

Hutchison China MediTech Ltd.
Chi-Med’s CEO, Christian Hogg, delivered a confident and convincing presentation at the recent interim analyst meeting. It was certainly refreshing to hear a CEO explain a drop in profits (and doing...
edison investment research
Hutchison China MediTech Ltd.
Hutchison China MediTech (Chi-Med) (HCM) is an innovative biopharma company focused on the highly lucrative global oncology and immunology markets. HCM has built a substantial pipeline of potential...
edison investment research
Hutchison China MediTech Ltd.
The next 12-18 months should be the defining period as Hutchison China MediTech transitions into a fully-fledged pharmaceutical business. Solid FY14 results confirm the continuing growth at China...

Latest discussion posts More

  • What's happening?

    Why is the share price going down? Has anyone got any convincing reason/s? The 'American adventure' has not proved anything positive for this company. SP has dropped from ...
    sporty investor
  • Re: Very quiet board

    No, we do not have a specific drug in development for that type of cancer. Ours are NSLC, PRCC, Gastric, Thyroid, RA, head & neck, Oesophageal
    David Global
  • Re: Interims

    I agree 100% Bernie, the Company continues to invest for the future. I really like their strategy which is unique in the small Biotech sector - use cash from Commercial ...
    David Global

Users' HoldingsMore

Users who hold Hutchison China Meditech LTD also hold..
RDS 'B'22%

Codes & Symbols